

## UNITED STATES PATENT AND TRADEMARK OFFICE

In re the	Application of	) Group Art Unit: 1645
LEDBE	TTER	) Examiner: To be Assigned
Serial N	o.: 10/627,556	) Confirmation No.: 3297
Filed:	July 26, 2003	) Customer No.: 23464
1	BINDING CONSTRUCTS AND METHODS FOR USE THEREOF	)

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97-1.98

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed prior to the receipt of a first Office Action on the merits with respect to the above-captioned application. Thus, it is believed that no fee is due for filing this statement. If the it is determined that a fee is due, the Commissioner is hereby authorized to charge the requisite fee, or any fees that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment, to Deposit Account No. 02-4553.

In accordance with 37 C.F.R. §1.56 and 37 C.F.R. §§1.97-1.98, this Information Disclosure Statement, including Forms PTO-SB/08 (2 pages), is provided herewith. Copies of some the documents listed on the Forms PTO-SB/08 were previously submitted in Information Disclosure Statements in connection with U.S. Application Serial No. 10/053,530 and therefore, in accordance with 37 C.F.R. § 1.98(d), hardcopies of the documents need not be submitted and are not included herewith. The Examiner is requested to make these documents of record in the instant application.

The Examiner's attention is directed to the following U.S. and international applications:

<u>U.S.S.N. (App. No.)</u>	Filing Date	<b>Published</b>
09/765,208	01/17/2001	
10/053,530	01/17/2002	US20030133939
10/207,655	07/25/2002	US20030118592
Int'l App. No.	Filing Date	Int'l Pub. No.
Int'l App. No. PCT/US02/01487	<b>Filing Date</b> 01/17/2002	Int'l Pub. No. WO/02/056910
PCT/US02/01487	01/17/2002	

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 C.F.R. §1.56. The filing of this Information Disclosure Statement is not an admission by Applicants or Applicants' representatives that any of the documents, singly or in any combination, is effective as prior art against the subject application. Additionally, in accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists in addition to those submitted herewith.

Applicant respectfully requests that the Examiner review the foregoing documents and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,

**BUCHANAN INGERSOLL L.L.P.** 

By:

James W. Collett Reg. No. 46,636

One Oxford Centre 301 Grant Street Pittsburgh, PA 15219-1410 (O) (619) 578.5000 (F) (619) 578.5940

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of a collection of information unless it contains a valid OMB control number. ork Reduction Act of 1995, no persons are required to respond to a collection of infor

LAT & STA State for form 1449/PTO

Sheet 1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Col	mplete if Known	
Application Number	10/627,556	
Filing Date	July 26, 2003	
First Named Inventor	LEDBETTER	
Art Unit	1642	
Examiner Name	HELMS, LARRY R.	· .
Attornov Docket Number	40076 000004 CIP2	

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		<sup>US-</sup> 5844093	12-01-1998	MERCK PATENT GMBH (D	
		<sup>US-</sup> 5736137	04-07-1998	RASTETTER W. et al	
		<sup>US-</sup> 5776456	07-07-1998	RASTETTER W. et al	
		<sup>US-</sup> 20030133930	07-17-2003	Goldenberg et al.	
		<sup>US-</sup> 2003-0219433	02-14-2003	Hansen H.	
		<sup>US-</sup> USSN 09/590,284	06-09-2000	Goldenberg et al.	
-		<sup>US-</sup> 6147203	11-14-2000	Pastan et al.	
		us- 6074644	06-13-2000	Pastan et al.	
		<sup>US-</sup> 5677425	10-14-1977	Bodmer et al.	
	İ	US- 6482919	11-19-2002	Ledbetter et al.	
		US-			
		US-			
		US-			
•	<u> </u>	US-			
		US-			
	<del>                                     </del>	US-			
		US-			
		US-			
	t	US-			

Examiner Initials*	Cite F	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T
_		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τʻ
		WO0044777	08-03-2000	IMCLONE SYSTEMS		
		WO9221755	12-10-1992	GENENTECH INC		
		EP0586002	03-09-1994	Macineira et al		
		WO9509917	04-01-1995	COLOMA et al.		
<u>.                                      </u>		WO9405690	03-17-1994	Gross et al.		

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known			
Gabatiate is is in 1440/110	Application Number	10/627,556		
INFORMATION DISCLOSURE	Filing Date	July 26, 2003		
STATEMENT BY APPLICANT	First Named Inventor	LEDBETTER		
(Use as many sheets as necessary)	Art Unit	1642		
(०५० वेड गांवगंत्र डाग्लंड वेड गल्टल्डडवार्ग)	Examiner Name	HELMS, LARRY R		
Sheet 2 of 2	Attorney Docket Number	49076-000004.CIP2		

NON PATENT LITERATURE DOCUMENTS
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
Munoz E. et The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3. Int Immunol. 1998 Feb;10(2):97-106.
Martin S. et al., Efficient neutralization and disruption of rhinovirus by chimeric ICAM- 1/immunoglobulin molecules , J. Virol. 1993,67:3561-3568
Stevenson G.T. et al., Mechanisms in removal of tumor by antibody. Cell Biophys. 1994;24-25:45-50.
Anderson et al., Targeted anti-cancer therapy using rituximab, a chimeric anti-CD-20 antibody (IDEC-c2B8) in the treatment of non-hodgkin's B-cell lymphoma; Biochemical Society Transactions Colcester, Essex, GB, pg 705-708; 1997

_		
Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FIRST Named Inventor   LEDBETTER   Art Unit   1642   Examiner Name   HELMS, LARRY R    Attorney Docket Number   48076-000004.CIP2    Fee Transmittal Form   Drawing(s)   After Allowance Communication to Total Number of Appeal Communication to Total Number of Pee Attached   Drawing(s)   After Allowance Communication to Total Number of Appeal Communication to Total Number of Appeal Communication to Total Number of Appeal Notice, Brief, Reply Brief)   Petition   Petition   Proprietary Information   Proprietary Information   Status Letter   Other Enclosure(s) (please Identify below):    Extension of Time Request   Request for Refund   Drawing of Communication to Total Number of CD(s)   Drawing of CD(s)   Drawing of Communication to Total Number of CD(s)   Drawing of Communication to Total Number of CD(s)   Drawing of Communication to Total Number of CD(s)   Drawing of of CD(s)   Dra	D. CHRY.	DERWORK REDUCTION ACT OF 1995	no persor	s are required to respond to a col Application Number Filing Date	10/627,55 July 26, 20	6	unless it displays a valid OMB control num
Examiner Name	FORM			LEDBETT	ER		
Total Number of Pages in This Submission    Attorney Docket Number   49076-000004.CIP2					1642		
ENCLOSURES (Check all that apply)    Fee Transmittal Form	(to be used for	all correspondence after initial	filing)		HELMS, L	ARRY R	·
Fee Transmittal Form    Fee Attached	Total Number o	f Pages in This Submission		Attorney Docket Number	Attorney Docket Number 49076-000004.CIP2		
Fee Transmittal Form    Drawing(s)			FNC	LOSURES (Chack all	that annis	()	
Poply to Missing Ports	Amendm A A Extension Express Information Certified Documer Reply to	ee Attached ent/Reply ifter Final ffidavits/declaration(s) n of Time Request Abandonment Request on Disclosure Statement Copy of Priority tt(s) Missing Parts/	Rema	Licensing-related Papers  Petition  Petition to Convert to a  Provisional Application  Power of Attorney, Revocatio  Change of Correspondence A  Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Landscape Table on CE	Address		Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify
	Signature	J. U.	Colo	2de g			
Signature L. Coloat	Printed name	James W. Cøllett, Ph.D.					
Printed name	Date December 20, 2004				Reg. No.	46636	
Buchanan Ingersoll	Printed name	James W. Collett, Ph.D. December 20, 2004					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

December 20, 2004

Gregory Austin

Typed or printed name